Loading
Life sciences · Journal article
Frontiers in Cell and Developmental Biology · September 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Histone deacetylases (HDACs) are key regulators of chromatin architecture and gene expression, and their dysregulation is closely linked to tumorigenesis, making them attractive targets for cancer therapy. Histone deacetylase inhibitors (HDACis) exert broad antitumor effects by modulating both epigenetic and non-epigenetic pathways. Although HDACis have demonstrated clinical activity in selected hematologic malignancies, their limited efficacy as monotherapy and limited therapeutic benefit in many solid tumors continue to constrain their broader clinical utilization. Accumulating evidence suggests that HDACis may have greater clinical value as treatment sensitizers and synergistic partners in combination regimens. Across chemotherapy, radiotherapy, targeted therapy, endocrine therapy, and immunotherapy, they enhance therapeutic responses through a range of interconnected mechanisms, including chromatin relaxation, impairment of DNA damage repair, induction of apoptosis, suppression of cell cycle progression, inhibition of oncogenic signaling pathways, and remodeling of the immune microenvironment. In this review, we outline the classification and biological functions of HDACs, along with an overview of representative HDACis. We focus on the synergistic and sensitizing roles these agents play across major anticancer modalities and discuss the molecular mechanisms underlying their therapeutic effects. We further discuss key translational barriers, including insufficient isoform selectivity, off-target toxicity, tumor heterogeneity, and inefficient drug delivery. Finally, we highlight emerging strategies—including isoform-selective inhibitors, mechanism-based biomarkers, rationally designed combinations, targeted delivery platforms, and dual- or multi-target agents. Overall, this review provides a comprehensive overview of HDACi-based combination therapies and their therapeutic and translational implications.